GlaxoSmithKline plc to Post Q3 2022 Earnings of $1.09 Per Share, Jefferies Financial Group Forecasts (NYSE:GSK)

GlaxoSmithKline plc (NYSE:GSKGet Rating) – Equities research analysts at Jefferies Financial Group upped their Q3 2022 earnings estimates for shares of GlaxoSmithKline in a research note issued to investors on Wednesday, May 4th. Jefferies Financial Group analyst P. Welford now forecasts that the pharmaceutical company will earn $1.09 per share for the quarter, up from their previous forecast of $1.06. Jefferies Financial Group also issued estimates for GlaxoSmithKline’s Q4 2022 earnings at $0.73 EPS, FY2022 earnings at $3.35 EPS and FY2023 earnings at $3.61 EPS.

A number of other brokerages have also issued reports on GSK. DZ Bank lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 11th. JPMorgan Chase & Co. raised their price objective on GlaxoSmithKline from GBX 1,740 ($21.74) to GBX 1,900 ($23.74) in a research note on Thursday, April 28th. StockNews.com lowered GlaxoSmithKline from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Stifel Nicolaus initiated coverage on shares of GlaxoSmithKline in a research report on Monday, February 28th. They set a “hold” rating for the company. Finally, Barclays lifted their price objective on shares of GlaxoSmithKline from GBX 1,775 ($22.17) to GBX 1,800 ($22.49) in a research note on Friday, April 29th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $1,248.67.

NYSE:GSK opened at $44.39 on Friday. The company has a market capitalization of $112.83 billion, a P/E ratio of 16.03, a PEG ratio of 2.01 and a beta of 0.64. The company has a current ratio of 1.19, a quick ratio of 0.95 and a debt-to-equity ratio of 1.29. GlaxoSmithKline has a 12 month low of $37.60 and a 12 month high of $46.97. The firm has a fifty day simple moving average of $43.79 and a 200-day simple moving average of $43.40.

GlaxoSmithKline (NYSE:GSKGet Rating) last issued its quarterly earnings results on Wednesday, February 9th. The pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.06. GlaxoSmithKline had a return on equity of 28.13% and a net margin of 14.03%. The business had revenue of $12.84 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same quarter in the previous year, the firm earned $0.62 earnings per share.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 1st. Investors of record on Friday, May 20th will be issued a $0.3496 dividend. This represents a $1.40 annualized dividend and a yield of 3.15%. The ex-dividend date of this dividend is Thursday, May 19th. GlaxoSmithKline’s payout ratio is 85.92%.

Institutional investors and hedge funds have recently modified their holdings of the stock. Two Sigma Investments LP boosted its stake in GlaxoSmithKline by 4,645.1% during the third quarter. Two Sigma Investments LP now owns 3,457,267 shares of the pharmaceutical company’s stock worth $132,102,000 after buying an additional 3,384,408 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of GlaxoSmithKline by 5,412.8% during the 3rd quarter. Two Sigma Advisers LP now owns 3,322,366 shares of the pharmaceutical company’s stock valued at $126,948,000 after acquiring an additional 3,262,100 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of GlaxoSmithKline by 107.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,726,412 shares of the pharmaceutical company’s stock valued at $142,386,000 after purchasing an additional 1,929,345 shares during the period. Acadian Asset Management LLC increased its position in GlaxoSmithKline by 481.3% during the fourth quarter. Acadian Asset Management LLC now owns 1,788,114 shares of the pharmaceutical company’s stock worth $78,830,000 after purchasing an additional 1,480,492 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in GlaxoSmithKline by 39.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,796,835 shares of the pharmaceutical company’s stock worth $211,540,000 after purchasing an additional 1,365,400 shares during the period. Hedge funds and other institutional investors own 32.76% of the company’s stock.

About GlaxoSmithKline (Get Rating)

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Stories

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.